Intramyocardial Hemorrhage and the "Wave Front" of Reperfusion Injury Compromising Myocardial Salvage.


Journal

Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365

Informations de publication

Date de publication:
04 01 2022
Historique:
received: 08 07 2021
revised: 04 10 2021
accepted: 12 10 2021
entrez: 7 1 2022
pubmed: 8 1 2022
medline: 15 2 2022
Statut: ppublish

Résumé

Reperfusion therapy for acute myocardial infarction (MI) is lifesaving. However, the benefit of reperfusion therapy can be paradoxically diminished by reperfusion injury, which can increase MI size. Hemorrhage is known to occur in reperfused MIs, but whether hemorrhage plays a role in reperfusion-mediated MI expansion is not known. We studied cardiac troponin kinetics (cTn) of ST-segment elevation MI patients (n = 70) classified by cardiovascular magnetic resonance to be hemorrhagic (70%) or nonhemorrhagic following primary percutaneous coronary intervention. To isolate the effects of hemorrhage from ischemic burden, we performed controlled canine studies (n = 25), and serially followed both cTn and MI size with time-lapse imaging. CTn was not different before reperfusion; however, an increase in cTn following primary percutaneous coronary intervention peaked earlier (12 hours vs 24 hours; P < 0.05) and was significantly higher in patients with hemorrhage (P < 0.01). In hemorrhagic animals, reperfusion led to rapid expansion of myocardial necrosis culminating in epicardial involvement, which was not present in nonhemorrhagic cases (P < 0.001). MI size and salvage were not different at 1 hour postreperfusion in animals with and without hemorrhage (P = 0.65). However, within 72 hours of reperfusion, a 4-fold greater loss in salvageable myocardium was evident in hemorrhagic MIs (P < 0.001). This paralleled observations in patients with larger MIs occurring in hemorrhagic cases (P < 0.01). Myocardial hemorrhage is a determinant of MI size. It drives MI expansion after reperfusion and compromises myocardial salvage. This introduces a clinical role of hemorrhage in acute care management, risk assessment, and future therapeutics.

Sections du résumé

BACKGROUND
Reperfusion therapy for acute myocardial infarction (MI) is lifesaving. However, the benefit of reperfusion therapy can be paradoxically diminished by reperfusion injury, which can increase MI size.
OBJECTIVES
Hemorrhage is known to occur in reperfused MIs, but whether hemorrhage plays a role in reperfusion-mediated MI expansion is not known.
METHODS
We studied cardiac troponin kinetics (cTn) of ST-segment elevation MI patients (n = 70) classified by cardiovascular magnetic resonance to be hemorrhagic (70%) or nonhemorrhagic following primary percutaneous coronary intervention. To isolate the effects of hemorrhage from ischemic burden, we performed controlled canine studies (n = 25), and serially followed both cTn and MI size with time-lapse imaging.
RESULTS
CTn was not different before reperfusion; however, an increase in cTn following primary percutaneous coronary intervention peaked earlier (12 hours vs 24 hours; P < 0.05) and was significantly higher in patients with hemorrhage (P < 0.01). In hemorrhagic animals, reperfusion led to rapid expansion of myocardial necrosis culminating in epicardial involvement, which was not present in nonhemorrhagic cases (P < 0.001). MI size and salvage were not different at 1 hour postreperfusion in animals with and without hemorrhage (P = 0.65). However, within 72 hours of reperfusion, a 4-fold greater loss in salvageable myocardium was evident in hemorrhagic MIs (P < 0.001). This paralleled observations in patients with larger MIs occurring in hemorrhagic cases (P < 0.01).
CONCLUSIONS
Myocardial hemorrhage is a determinant of MI size. It drives MI expansion after reperfusion and compromises myocardial salvage. This introduces a clinical role of hemorrhage in acute care management, risk assessment, and future therapeutics.

Identifiants

pubmed: 34991787
pii: S0735-1097(21)08081-5
doi: 10.1016/j.jacc.2021.10.034
pii:
doi:

Substances chimiques

Troponin 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

35-48

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL133407
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL136578
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL147133
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2022 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Funding Support and Author Disclosures This work was supported by grants from National Institutes of Health/NHLBI HL133407, HL136578, and HL147133. Drs Finney and Dharmakumar have ownership interest in Cardiotheranostics, LLC. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Auteurs

Ting Liu (T)

Cedars-Sinai Medical Center, Los Angeles, California, USA; Department of Radiology, the First Affiliated Hospital of China Medical University, Shenyang, China.

Andrew G Howarth (AG)

Cedars-Sinai Medical Center, Los Angeles, California, USA; University of Calgary, Calgary, Alberta, Canada.

Yinyin Chen (Y)

Cedars-Sinai Medical Center, Los Angeles, California, USA; Zhongshan Hospital, Fudan University and Shanghai Institute of Medical Imaging, Shanghai, China.

Anand R Nair (AR)

Cedars-Sinai Medical Center, Los Angeles, California, USA.

Hsin-Jung Yang (HJ)

Cedars-Sinai Medical Center, Los Angeles, California, USA.

Daoyuan Ren (D)

Zhongshan Hospital, Fudan University and Shanghai Institute of Medical Imaging, Shanghai, China.

Richard Tang (R)

Cedars-Sinai Medical Center, Los Angeles, California, USA.

Jane Sykes (J)

Lawson Research Institute, University of Western Ontario, London, Ontario, Canada.

Michael S Kovacs (MS)

Lawson Research Institute, University of Western Ontario, London, Ontario, Canada.

Damini Dey (D)

Cedars-Sinai Medical Center, Los Angeles, California, USA.

Piotr Slomka (P)

Cedars-Sinai Medical Center, Los Angeles, California, USA.

John C Wood (JC)

University of Southern California, Los Angeles, California, USA.

Robert Finney (R)

Cardio-theranostics, Los Angeles, California, USA.

Mengsu Zeng (M)

Zhongshan Hospital, Fudan University and Shanghai Institute of Medical Imaging, Shanghai, China.

Frank S Prato (FS)

Lawson Research Institute, University of Western Ontario, London, Ontario, Canada.

Joseph Francis (J)

Louisiana State University, Baton Rouge, Louisiana, USA.

Daniel S Berman (DS)

Cedars-Sinai Medical Center, Los Angeles, California, USA.

Prediman K Shah (PK)

Cedars-Sinai Medical Center, Los Angeles, California, USA.

Andreas Kumar (A)

Northern Ontario School of Medicine, Sudbury, Ontario, Canada.

Rohan Dharmakumar (R)

Cedars-Sinai Medical Center, Los Angeles, California, USA; Krannert Cardiovascular Research Center, Indiana University School of Medicine/IU Health Cardiovascular Institute, Indianapolis, Indiana, USA. Electronic address: rdkumar@iu.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH